CL2008003421A1 - Sistema de administracion intravaginal con un compartimiento que comprende drospirenona y un compartimiento, igual o diferente, con un estrogeno, cada compartimiento comprende un nucleo y una membrana que lo recubre que consisten de una composicion de polimero que contiene un elastomero basado en polidimetilsiloxano con grupos polioxido de alquileno. - Google Patents

Sistema de administracion intravaginal con un compartimiento que comprende drospirenona y un compartimiento, igual o diferente, con un estrogeno, cada compartimiento comprende un nucleo y una membrana que lo recubre que consisten de una composicion de polimero que contiene un elastomero basado en polidimetilsiloxano con grupos polioxido de alquileno.

Info

Publication number
CL2008003421A1
CL2008003421A1 CL2008003421A CL2008003421A CL2008003421A1 CL 2008003421 A1 CL2008003421 A1 CL 2008003421A1 CL 2008003421 A CL2008003421 A CL 2008003421A CL 2008003421 A CL2008003421 A CL 2008003421A CL 2008003421 A1 CL2008003421 A1 CL 2008003421A1
Authority
CL
Chile
Prior art keywords
compartment
drospirenone
estrogen
polyoxide
polydimethylsiloxane
Prior art date
Application number
CL2008003421A
Other languages
English (en)
Inventor
Christine Talling
Vladimir Hanes
Antti Keinanen
Svante Holmberg
Hannu Nikander
Original Assignee
Bayer Schering Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07397042A external-priority patent/EP2062568A1/en
Priority claimed from EP07397043A external-priority patent/EP2062569B1/en
Application filed by Bayer Schering Pharma Oy filed Critical Bayer Schering Pharma Oy
Publication of CL2008003421A1 publication Critical patent/CL2008003421A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica de liberación controlada compuesto por drospirenona y un estrógeno; útil para mejorar la protección contra infecciones bacterianas, fúngicas y enfermedades de trasmisión sexual.
CL2008003421A 2007-11-22 2008-11-18 Sistema de administracion intravaginal con un compartimiento que comprende drospirenona y un compartimiento, igual o diferente, con un estrogeno, cada compartimiento comprende un nucleo y una membrana que lo recubre que consisten de una composicion de polimero que contiene un elastomero basado en polidimetilsiloxano con grupos polioxido de alquileno. CL2008003421A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07397042A EP2062568A1 (en) 2007-11-22 2007-11-22 Vaginal delivery system
EP07397043A EP2062569B1 (en) 2007-11-22 2007-11-22 Vaginal delivery system

Publications (1)

Publication Number Publication Date
CL2008003421A1 true CL2008003421A1 (es) 2009-08-07

Family

ID=40394262

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003421A CL2008003421A1 (es) 2007-11-22 2008-11-18 Sistema de administracion intravaginal con un compartimiento que comprende drospirenona y un compartimiento, igual o diferente, con un estrogeno, cada compartimiento comprende un nucleo y una membrana que lo recubre que consisten de una composicion de polimero que contiene un elastomero basado en polidimetilsiloxano con grupos polioxido de alquileno.

Country Status (26)

Country Link
US (2) US20100285097A1 (es)
EP (1) EP2227220A1 (es)
JP (1) JP2011504484A (es)
KR (1) KR20100090708A (es)
CN (1) CN101873850A (es)
AR (1) AR069379A1 (es)
AU (1) AU2008327813A1 (es)
BR (1) BRPI0815936A2 (es)
CA (1) CA2705734A1 (es)
CL (1) CL2008003421A1 (es)
CO (1) CO6290642A2 (es)
CR (1) CR11493A (es)
DO (1) DOP2010000154A (es)
EA (1) EA018112B1 (es)
EC (1) ECSP10010104A (es)
IL (1) IL205588A0 (es)
MX (1) MX2010003656A (es)
NZ (1) NZ584216A (es)
PA (1) PA8805001A1 (es)
PE (1) PE20091025A1 (es)
SG (1) SG186002A1 (es)
SV (1) SV2010003513A (es)
TW (1) TW200927141A (es)
UY (1) UY31475A1 (es)
WO (1) WO2009066006A1 (es)
ZA (1) ZA201002122B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI121000B (fi) * 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8822610B2 (en) * 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2014036498A2 (en) 2012-08-30 2014-03-06 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
US8569421B2 (en) 2009-04-23 2013-10-29 ATRP Solutions, Inc. Star macromolecules for personal and home care
FI20095550A0 (fi) * 2009-05-19 2009-05-19 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
FI20095563A (fi) * 2009-05-20 2010-11-21 Bayer Schering Pharma Oy Vaginaalinen antojärjestelmä
AU2011238710B2 (en) * 2010-03-28 2015-08-20 Evestra, Inc. Intravaginal drug delivery device
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
US20120053534A1 (en) * 2010-06-22 2012-03-01 Anu Mahashabde Intravaginal devices comprising anticholinergic agents, and methods of making thereof
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
BR112013011744B1 (pt) * 2010-11-12 2021-04-27 The University Of Utah Research Foundation Dispositivo intravaginal para distribuição controlada de lubrificantes
SG190719A1 (en) * 2010-11-29 2013-07-31 Meiji Co Ltd Endometriosis prevention and/or improving agent, and food or drink composition containing same
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
KR101263916B1 (ko) 2011-01-11 2013-05-13 이장희 성 호르몬 방출 장치 및 이를 이용한 동물 피임 및 발정 유도 방법
CN103747765B (zh) * 2011-06-06 2016-04-06 橡冠科学研究院 采用芯吸释放窗口的药物递送装置
CN103648482B (zh) * 2011-07-15 2018-01-02 根特大学 阴道内递送系统
JP6170044B2 (ja) * 2011-07-20 2017-07-26 エフ． カイザー，パトリック 薬物送達のための膣内デバイス
EP2749286B1 (en) 2011-08-26 2017-03-01 Universidad De Santiago De Chile Use of non-steroidal anti-inflammatory drugs meloxicam and piroxicam, administered intravaginally, for interruption of a woman's ovulation process
CN103007427B (zh) * 2011-09-21 2016-01-20 上海市计划生育科学研究所 缓控释宫内释药器及其制备方法
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
EP3308771A1 (en) 2012-06-13 2018-04-18 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
KR20150051234A (ko) 2012-09-03 2015-05-11 에쏘세아 파르밍 에쎄.아. 수생 생물종의 배향 및／또는 억제를 위한 저장조 케이지 침지 시스템
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014066480A1 (en) * 2012-10-23 2014-05-01 Estech Usa, Llc Treating conditions caused by abnormal growth of pathogens in body cavities
CN105263978B (zh) 2013-02-04 2018-04-17 Atrp解决方案公司 耐盐星形大分子
SE539540C2 (sv) * 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
EP3065807A1 (en) * 2013-11-05 2016-09-14 TARIS Biomedical LLC Osmotic drug delivery devices, kits, and methods
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
WO2015095793A1 (en) 2013-12-19 2015-06-25 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
EP3125964A4 (en) * 2014-04-01 2018-02-28 Poly-Med Inc. Contraceptive and related device
MX2017000076A (es) 2014-07-03 2017-05-01 Atrp Solutions Inc Macromoleculas estrellas compatibles con tensoactivos.
EP3169324B1 (en) 2014-07-14 2019-05-08 Orion Biotechnology Canada Ltd. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof
CN104117135A (zh) * 2014-08-11 2014-10-29 崔仁海 阴道内植入式治疗装置
CN104558491A (zh) * 2014-12-25 2015-04-29 中南大学 能促进组织内膜生长的聚氨酯材料的制备方法
EP3294300A1 (en) * 2015-05-13 2018-03-21 Bayer Oy A long acting drug delivery device and its use in contraception
CN108587968A (zh) * 2015-08-31 2018-09-28 科.汉森有限公司 乳杆菌细菌和组合物以及采用其生产产品的方法和用途
KR20180093255A (ko) * 2015-12-21 2018-08-21 바이엘 오와이 질용 고리의 제조 방법
JOP20160267B1 (ar) * 2015-12-21 2021-08-17 Bayer Oy طريقة لتصنيع جهاز لتصريف عقار وجهاز تصريف العقار الذي تم تصنيعه بواسطة هذه الطريقة
US20190290474A1 (en) * 2016-01-04 2019-09-26 Jurox Pty Ltd Drug release device and use
KR101720145B1 (ko) * 2016-07-08 2017-04-07 (주)정가진면역연구소 여성 질염 예방 및 개선 기능성 조성물
WO2018067568A1 (en) 2016-10-04 2018-04-12 Evofem Biosciences, Inc. Method of treatment and prevention of bacterial vaginosis
JP7242648B2 (ja) * 2017-09-27 2023-03-20 バイエル・オサケユキテュア エラストマーマトリックスからの治療活性剤の放出を変更するための方法
WO2019210066A1 (en) * 2018-04-27 2019-10-31 Evestra, Inc. Estrogen prodrugs and methods of administering estrogen prodrugs
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
WO2020007780A1 (en) * 2018-07-02 2020-01-09 Artpred B.V. Method and kit for altering the outcome of an assisted reproductive technology procedure
KR102078462B1 (ko) * 2018-07-24 2020-02-17 주식회사 디네이쳐 질환경 개선 조성물 및 이를 포함하는 개선제
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption
CN110585246B (zh) * 2019-09-22 2020-06-02 深圳市多微生保健食品有限公司 一种阴道抑菌制剂及其制备方法
EP4057994A4 (en) * 2019-11-12 2023-12-06 Poly-Med Inc. CONTRACEPTIVE MEDICAL DEVICES
KR20210097421A (ko) * 2020-01-30 2021-08-09 주식회사 디네이쳐 펄스형 질내 약산성 환경 유지 조성물
IT202000029267A1 (it) * 2020-12-01 2022-06-01 Francesca FRIZZI Dispositivo vaginale
WO2023200974A1 (en) * 2022-04-14 2023-10-19 Yale University Nanoparticles and nanoparticle-releasing vaginal rings
WO2024030116A1 (en) * 2022-08-01 2024-02-08 Lupin Inc. Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4596576A (en) * 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
FR2618329B1 (fr) * 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
DE69616551T2 (de) * 1995-07-04 2002-05-29 Akzo Nobel Nv Ringförmige vorrichtung
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
JP2004521951A (ja) * 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
AU2002313517B2 (en) * 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
WO2003026687A1 (en) * 2001-09-28 2003-04-03 Nutraceutix, Inc. Delivery system for biological component
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
EP1667619A4 (en) * 2003-09-19 2007-10-10 Drugtech Corp PHARMACEUTICAL FEEDING SYSTEM
ES2327247T3 (es) * 2004-03-24 2009-10-27 N.V. Organon Sistema de administracion de farmacos basado en copolimeros de polietileno y acetato de vinilo.
CA2601773A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
EP1954240A2 (en) * 2005-07-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof

Also Published As

Publication number Publication date
US20100285097A1 (en) 2010-11-11
TW200927141A (en) 2009-07-01
BRPI0815936A2 (pt) 2019-08-27
IL205588A0 (en) 2010-11-30
CA2705734A1 (en) 2009-05-28
AU2008327813A1 (en) 2009-05-28
PA8805001A1 (es) 2009-06-23
US20090142313A1 (en) 2009-06-04
CN101873850A (zh) 2010-10-27
SG186002A1 (en) 2012-12-28
CR11493A (es) 2010-08-23
EA018112B1 (ru) 2013-05-30
PE20091025A1 (es) 2009-08-17
AR069379A1 (es) 2010-01-20
EP2227220A1 (en) 2010-09-15
DOP2010000154A (es) 2010-07-31
EA201070639A1 (ru) 2010-10-29
ECSP10010104A (es) 2010-06-29
CO6290642A2 (es) 2011-06-20
SV2010003513A (es) 2010-08-09
MX2010003656A (es) 2010-04-21
KR20100090708A (ko) 2010-08-16
NZ584216A (en) 2012-03-30
ZA201002122B (en) 2011-06-29
UY31475A1 (es) 2009-07-17
WO2009066006A1 (en) 2009-05-28
JP2011504484A (ja) 2011-02-10

Similar Documents

Publication Publication Date Title
CL2008003421A1 (es) Sistema de administracion intravaginal con un compartimiento que comprende drospirenona y un compartimiento, igual o diferente, con un estrogeno, cada compartimiento comprende un nucleo y una membrana que lo recubre que consisten de una composicion de polimero que contiene un elastomero basado en polidimetilsiloxano con grupos polioxido de alquileno.
BRPI0911442A2 (pt) conjugados potentes e ligantes hidrofílicos
HRP20070012A2 (en) Immunostimulatory oligonucleotide multimers
CL2009001874A1 (es) Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661.
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
CR20110072A (es) Sistema de administración de drogas que contiene progestina
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BRPI0510999A (pt) dispositivo de eletrodesionização e métodos de uso
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
PE20100057A1 (es) Sistema de suministro intrauterino para la liberacion controlada de progestageno
AR060165A1 (es) Proteina de suero como vehiculo de entrega para un agente activo
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
MX2009005445A (es) Sistema de suministro para risperidona.
BRPI0512068A (pt) produto de liberação de drogas e métodos
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
GT200800115A (es) Metodos para tratar infecciones del tracto gastrointestinal con tigeciclina
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
EP2518150A3 (en) 5'Triphosphate oligonucleotide with blunt end and uses thereof
CL2008003632A1 (es) Uso de hidroxidos de guanidinio polimericos para combatir microorganismos no deseados; procedimiento para combatir hongos fitopatogenos; combinaciones de principio activo que comprenden al menos un hidroxido de guanidinio.
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
MX2009005446A (es) Sistema de suministro vaginal para mirtazapina.
PT1713438E (pt) Sabonete medicinal
AR076588A1 (es) Sistema de liberacion vaginal
CL2012003105A1 (es) Bacteria comensal geneticamente diseñada, del tracto genital femenino que expresa un agente anti espermatozoide; composicion que comprende dicha bacteria; uso de dicha composicion para la reduccion de la incidencia de embarazo en una poblacion femenina; dispositivo de insercion intravaginal.